InSitu Biologics Completes GMP Manufacturing for INSB200, Advancing Non-Opioid Pain Relief
InSitu Biologics, a life sciences company, has successfully completed a Good Manufacturing Practice (GMP) production batch of its lead product candidate, INSB200™. This milestone is crucial for the company's planned December 2026 submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA). INSB200 is an investigational, single-injection, sustained-release peripheral nerve block (PNB) designed to provide prolonged non-opioid post-surgical pain relief. Unlike conventional nerve blocks that offer pain relief for 12-24 hours, INSB200 aims to extend this duration over multiple days while minimizing systemic drug exposure. The product utilizes ropivacaine, a known local anesthetic, within InSitu Biologics' proprietary drug-delivery platform. The company anticipates FDA clearance of its IND application and the initiation of its first-in-human combined Phase 1/2 clinical trial in bunionectomy patients during Q1 2027, which will evaluate dosing, safety, and preliminary...